Answers are grounded in this paper and cite their sources.
Camonsertib is a selective oral inhibitor of ataxia telangiectasia and Rad3-related (ATR) kinase with demonstrated efficacy in tumors with DNA damage response gene deficiencies. On-target anemia is the main drug-related toxicity typically manifesting after the period of dose-limiting toxicity evaluation. Thus, dose and schedule optimization requires extended follow-up to assess prolonged treatment effects.
No takes yet. Share an insight, caveat, or question.
Fontana et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: